Aktienanalyse zu AptarGroup, Inc. (ATR)ATRAptarGroup, Inc.

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).

Aptargroup Inc is a good buy right now due to its current price of $126.55, which is below the average analyst price target of $150, indicating significant upside potential. The forward P/E ratio of 19.76 suggests the stock is reasonably valued compared to its expected earnings growth. Additionally, the RSI of 66.28 indicates that the stock is approaching overbought territory, but it is not yet excessively overbought, allowing for potential further gains. The main risk is the recent price decline below the 200-day moving average, which could signal a bearish trend if it continues, as seen in the recent news about market caution.

9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.